Prevalence of germline mutations in women with breast and/or ovarian cancer in a tertiary care center in Pune, India

Author:

Kulkarni Shriniwas Subhash1,Nag Shona1,Patra Abhilash2,Pant Hira Ballabh3,Agiwal Varun3,Nirupama A. Y.4,Chaudhuri Sirshendu4,Murthy G. V. S.5

Affiliation:

1. Department of Oncology, Sahyadri Super Speciality Hospital, Pune, Maharashtra, India

2. E2E Pfizer Fellow, Indian Institute of Public Health Hyderabad, Hyderabad, Telangana, India,

3. Department of Statistics, Indian Institute of Public Health Hyderabad, Hyderabad, Telangana, India,

4. Department of Epidemiology, Indian Institute of Public Health Hyderabad, Hyderabad, Telangana, India,

5. Director, Indian Institute of Public Health Hyderabad, Hyderabad, Telangana, India,

Abstract

In India, the incidence of breast cancer accounted for 1,78,361 cases, whereas ovarian cancer accounts for 45,701 cases, according to Globocan Report 2020. These cancers are known to have a hereditary basis, and >10% of them are associated with pathogenic BRCA1 and BRCA2 mutations. The prevalence of BRCA1 and BRCA2 varies across various Indian studies and is reported to be 2.9–28%. However, gene mutations other than BRCA1 and BRCA2 which are shown to increase the risk of hereditary breast and ovarian cancer (HBOC) are underreported. Objectives: The objective of this study was to estimate the prevalence of deleterious germline mutations among women with breast and/or ovarian cancer. Material and Methods: A cross-sectional study was conducted in the department of oncology at a super specialty hospital. Patients were enrolled based on the current National Comprehensive Cancer Network guidelines for genetic risk and evaluation of HBOC. Demographic and clinical information was extracted from the electronic medical records of the hospitals from 2018 to 2021. Next-generation sequencing (NGS) was performed on the extracted DNA using a custom capture kit and classified based on the American College of Medical Genetics. Results: A total of 94 patients suspected of having HBOC were examined for deleterious germline mutations. The median age of the patient was 46 years (range: 38–57 years). Breast and ovarian cancer patients constituted 64.9% and 35.1%, respectively. The overall mutation detection rate was 25.5%. The positive mutation detection rate was 26.2% and 24.2% in breast and ovarian cancer, respectively, whereas the variant of uncertain significance rate was 18.03% and 24.2%, respectively. Among the pathogenic mutations, BRCA1 was the most common mutation in women with breast cancer (81.3%). In ovarian cancer, it was 50%. BRCA2 mutation was more prevalent in ovarian cancer (50%). Conclusion: Our study reports a higher prevalence of germline BRCA1 and BRCA2 mutations in breast and ovarian cancer as compared to other studies. Genetic testing can be offered to high-risk women regardless of family history. This will be useful during diagnosis and help physicians in planning subsequent treatment.

Publisher

Scientific Scholar

Subject

General Medicine

Reference35 articles.

1. World Health Organization;International Agency for Research on Cancer (IARC);Latest Global Cancer Globocan,2020

2. Integrated genomic analyses of ovarian carcinoma;Cancer Genome Atlas Research Network;Nature,2011

3. Comprehensive molecular portraits of human breast tumours;Koboldt;Nature,2012

4. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers;Kuchenbaecker;JAMA,2017

5. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group;Anglian Breast Cancer Study Group;Br J Cancer,2000

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Trends of germline mutations in women with breast and ovarian carcinoma;International Journal of Molecular and Immuno Oncology;2023-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3